MarketWatch |
Popis: MarketWatch, a leading publisher of business and financial news, offers users up-to-the minute news, investment tools, and subscription products.
|
||||||
‘I don’t feel sorry for myself’: I’m 64 and will be renting for the rest of my life. Is that so bad?0:58 “I married a wonderful man with a good income. He left his job due to health issues and suffered a massive stroke at 53.” Will Anthropic pull off a November IPO? Time is running out to file key paperwork.0:26 If market pressures keep building, Anthropic “could reasonably decide it is better to stay private and wait for a better opportunity,” one portfolio manager says. Investors piled a record sum into a leveraged semiconductor ETF last week. Things didn’t work out.23:54 Traders making bullish bets on chip stocks are getting walloped this month, as renewed fears emerged about investment returns on the buildout of artificial intelligence. This hot AI-fueled stock has been in a rut. It just beat earnings expectations by 36%.23:23 A company beating earnings expectations by 36% and revenue expectations by 15% would usually see a postresults bump. But not for Bloom Energy, the fuel-cell maker that has flourished due to data-center demand. The mobile ambitions of SpaceX are hitting telecom stocks again. Here’s what the latest developments mean.23:22 Reports of Starlink’s discussions with cell-tower owners were noticed by shareholders of Verizon, AT&T and T-Mobile. Some Republicans are opposing Trump on tariffs. Maine’s Susan Collins just got him to back down on Canadian levies.23:22 As she faces a tough midterm race, the five-term GOP senator is touting her successful lobbying effort against certain tariffs on Canada The U.S. economy is great by this measure, and the good times aren’t over. So why are Americans so sour?22:50 A once-in-a-generation investment boom has created lots of winners — but many Americans are feeling left out. The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.21:15 The first Phase 3 data for a cancer vaccine has raised questions about whether the potential new treatment is needed. |